Chemistry:Ombitasvir

From HandWiki
Short description: Chemical compound
Ombitasvir
Ombitasvir.svg
Clinical data
Trade names
  • Viekira Pak, Viekira XR (with ombitasvir, paritaprevir, ritonavir and dasabuvir),
  • Technivie (with ombitasvir, paritaprevir, and ritonavir)
Other namesABT-267
License data
Routes of
administration
By mouth (tablets)
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNot determined
Protein binding~99.9%
MetabolismAmide hydrolysis followed by oxidation
Onset of action~4 to 5 hours
Elimination half-life21 to 25 hours
ExcretionMostly with feces (90.2%)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
Chemical and physical data
FormulaC50H67N7O8
Molar mass894.127 g·mol−1
3D model (JSmol)

Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection by AbbVie. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1,[1][2] and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.[3][4]

Ombitasvir is an NS5A inhibitor that acts by inhibiting the HCV protein NS5A.[5]

See also

  • Discovery and development of NS5A inhibitors

References

Further reading